|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for MAPK13 |
 Gene summary |
| Basic gene Info. | Gene symbol | MAPK13 |
| Gene name | mitogen-activated protein kinase 13 | |
| Synonyms | MAPK 13|MAPK-13|PRKM13|SAPK4|p38delta | |
| Cytomap | UCSC genome browser: 6p21.31 | |
| Type of gene | protein-coding | |
| RefGenes | NM_002754.4, NR_072996.1, | |
| Description | MAP kinase 13MAP kinase p38 deltamitogen-activated protein kinase p38 deltastress-activated protein kinase 4 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 602899 | |
| HGNC : HGNC | ||
| HPRD : 09113 | ||
| Protein | UniProt: O15264 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_MAPK13 | |
| BioGPS: 5603 | ||
| Pathway | NCI Pathway Interaction Database: MAPK13 | |
| KEGG: MAPK13 | ||
| REACTOME: MAPK13 | ||
| Pathway Commons: MAPK13 | ||
| Context | iHOP: MAPK13 | |
| ligand binding site mutation search in PubMed: MAPK13 | ||
| UCL Cancer Institute: MAPK13 | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0000165 | MAPK cascade | 9218798 | GO:0006950 | response to stress | 9218798 | GO:0006970 | response to osmotic stress | 9731215 | GO:0018105 | peptidyl-serine phosphorylation | 15850461 | GO:0035556 | intracellular signal transduction | 9218798 |
| Top |
| Ligand binding site mutations for MAPK13 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | A52 | A52V | COAD | 1 | R68 | A66T | GBM | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for MAPK13 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | R68 | A66T | -0.82102116 | A52 | A52V | -0.42623678 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for MAPK13 from PDB |
| Top |
| Differential gene expression and gene-gene network for MAPK13 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for MAPK13 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C0008370 | Cholestasis | 2 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for MAPK13 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Investigational | DB05157 | KC706 | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of MAPK13 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | N61 | 1-(3-TERT-BUTYL-1-METHYL-1H-PYRAZOL-5-YL)-3-[4- (PYRIDIN-4-YLOXY)PHENYL]UREA | 4eyj | A | A52 | 0RX | 2-(MORPHOLIN-4-YL)-N-[4-(PYRIDIN-4-YLOXY) PHENYL]PYRIDINE-4-CARBOXAMIDE | 4eym | A | A52 R68 |
| Top |
| Conservation information for LBS of MAPK13 |
| Multiple alignments for O15264 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |